CClinicalTrials.gg
CompletedNCT00380822Updated Sep 27, 2006

Double-Blind Study of Miglitol in Japanese With type2 Diabetes

A Phase 3 interventional study of miglitol in Type 2 Diabetes Mellitus, sponsored by Sanwa Kagaku Kenkyusho Co., Ltd.. Completed at 27 sites in Japan. Open to participants aged 20 Years to 69 Years. Per ClinicalTrials.gov, last updated 2006-09-27.

Sponsored by Sanwa Kagaku Kenkyusho Co., Ltd. · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Allocation
Randomized
Ages
20 Years to 69 Years
Sex
All
01

Study summary

To investigate the efficacy and safety of miglitol in Japanese patients with type 2 diabetes that is insufficiently controlled diet alone.

02

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • alpa-glucosidase inhibitor
03

In context

Diabetes Mellitus, Type 2

9,359 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,318 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Sanwa Kagaku Kenkyusho Co., Ltd. is the lead sponsor of 19 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Type2 diabetic patient on Dietary Therapy
  • Criteria for postprandial plasma glucose and HbA1c are met

Exclusion criteria

Exclusion Criteria:

  • Type1 diabetes
  • Patients treated with antidiabetic drugs or Insulin
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double

Interventions

  • Drugmiglitol
06

Study locations

27 sites
  • Aichi, Japan
  • Chiba, Japan
  • Fukuoka, Japan
  • Gunma, Japan
  • Hiroshima, Japan
  • Hyogo, Japan
  • Ibaragi, Japan
  • Ishikawa, Japan
  • Iwate, Japan
  • Kumamoto, Japan
  • Kyoto, Japan
  • Mie, Japan
  • Miyagi, Japan
  • Nagasaki, Japan
  • Niigata, Japan
  • Oita, Japan
  • Okayama, Japan
  • Osaka, Japan
  • Saga, Japan
  • Saitama, Japan
  • Shiga, Japan
  • Shimane, Japan
  • Shizuoka, Japan
  • Tokyo, Japan
  • Toyama, Japan
  • Yamagata, Japan
  • Yamaguchi, Japan
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 27, 2006, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00380822
Lead sponsor
Sanwa Kagaku Kenkyusho Co., Ltd.
First posted
Sep 27, 2006
Last update
Sep 27, 2006

Study contacts

Clinical study Group, Clinical Development Dept.
study director · Sanwa Kagaku Kenkyusho Co., Ltd.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion